Left Atrial Appendage Thrombus in a Patient with Atrial Fibrillation on Apixiban Successfully Treated with Warfarin and Pulmonary Vein Isolation Ablation
DOI:
https://doi.org/10.17140/HROJ-4-138Keywords:
Atrial fibrillation; Left atrial appendage thrombus, Novel anticoagulation; Apixiban; WarfarinAbstract
Atrial fibrillation (AF) is a common cardiac arrhythmia that can be seen in hospitalized patients.
It has been shown to be a major risk factor for cardioembolic stroke, and therefore patients
are frequently started on lifelong anticoagulation. The majority of patients benefit from either
cardioverison or pulmonary vein isolation ablation. We herein describe the case of a 58-yearold
male with a past medical history of atrial fibrillation surgery who presented to hospital
for elective atrial fibrillation ablation after failed medical therapy and persistent symptoms. A
transesphageal echocardiogram (TEE) prior to the procedure demonstrated a left atrial appendage
clot despite patient’s compliance with apixiban. Subsequently, the patient is started on
warfarin therapy with a heparin bridge. A TEE performed 6 weeks after discharge showed
resolution of the left atrial appendage clot allowing the ablation procedure to be successfully
performed.
References
Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Es-timates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013; 112: 1142 -1147. doi: 10.1016/j.amjcard.2013.05.063
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370-2375. doi: 10.1001/jama.285.18.2370
Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in in-cidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future preva-lence [published correction appears in Circulation. 2006; 114: e498]. Circulation. 2006; 114: 119-125. doi: 10.1161/CIRCU-LATIONAHA.105.595140
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014; 129(8): 837-847. doi: 10.1161/ CIRCULATIONAHA.113.005119
Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation [abstract]. J Am CollCar-diol. 1992; 19: 41A.
Solomon MD, Ullal AJ, Hoang DD, Freeman JV, Heidenreich P, Turakhia MP. Cost-effectiveness of pharmacologic and inva-sive therapies for stroke prophylaxis in atrial fibrillation. J Car-diovasc Med (Hagerstown). 2012; 13(2): 86-96. doi: 10.2459/ JCM.0b013e32834f23cf
Ball J, Carrington MJ, McMurray JJ, et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st centu-ry. Int J Cardiol. 2013; 167(5): 1807-1824. doi: 10.1016/j.ij-card.2012.12.093
Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation the copenhagen stroke study. Stroke. 1996; 27: 1765-1769. doi: 10.1161/01.STR.27.10.1765
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrom-botic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12): 857-867. doi:
7326/0003-4819-146-12-200706190-00007 10. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992. doi: 10.1056/NEJMoa1107039
Yasaka M, Yamaguchi T, Miyashita T, Tsuchiya T. Regres-sion of intracardiac thrombus after embolic stroke. Stroke. 1990; 21: 1540-1544. doi: 10.1161/01.STR.21.11.1540
Fang BR, Kuo LT. Recurrent cerebral embolism and impend-ing detachment of a previous non mobile left atrial thrombus following initiation of anticoagulant therapy in a patient with non valvular atrial fibrillation. Echocardiography. 2001; 18(6): 527-529. doi: 10.1046/j.1540-8175.2001.00527.x
Ohyagi M, Nakamura K, Watanabe M, Fujigasaki H. Em-bolic stroke during apixaban therapy for left atrial appendage thrombus. J Stroke Cerebrovasc Dis. 2015; 24(4): e101-e102. doi: 10.1016/j.jstrokecerebrovasdis.2014.11.031
Kawakami T, Kobayakawa H, Ohno H, et al. Resolution of left atrial appendage thrombus with apixiban. Thromb J. 2013; 11: 26. doi: 10.1186/1477-9560-11-26
Dobashi S, Fujino T, Ikeda T. Use of apixaban for an elderly patient with left atrial thrombus. BMJ Case Rep. 2014; 2014: bcr2014203870. doi: 10.1136/bcr-2014-203870
Saito S, Tomita H, Kimura Y, et al. Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardio embolic stroke patient. J Stroke Cere-brovasc Dis. 2014; 23: 1747-1749. doi: 10.1016/j.jstrokecere-brovasdis.2014.01.014
Collins LJ, Silverman DI, Douglas PS, Manning WJ. Car-dioversion of non rheumatic atrial fibrillation. Reduced thrombo embolic complications with 4 weeks of precardioversion antico-agulation are related to atrial thrombus resolution. Circulation. 1995; 92(2): 160-163. doi: 10.1161/01.CIR.92.2.160
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fi-brillation. Circulation. 2014; 130: e199-e267. doi: 10.1016/j. jacc.2014.03.022
Seidl K, Rameken M, Drögemüller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: Value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Obser-vational Cardioversion Study. J Am Coll Cardiol. 2002; 39(9): 1436. doi: 10.1016/S0735-1097(02)01785-0
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.